Previous 10 | Next 10 |
2024-03-19 19:52:33 ET Summary John Paulson's 13F portfolio value decreased slightly from $1.12B to $1.11B in the last quarter. The top five positions in Paulson's portfolio are Madrigal Pharma, Bausch Health, Brightsphere Investment Group, NovaGold, and Perpetua Resources. Pa...
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients wi...
Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from its first colonoscopy awareness an...
LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference in Boston on March 5, 2024. The Bausch Health team will be hosting a fireside chat at 12:50 p.m...
2024-02-29 08:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-24 09:09:44 ET Summary Bausch Health is burdened by a heavy debt load of over $20 billion, impacting its equity valuation. The resolution to the leverage issues lies in divesting Bausch + Lomb Corp shares, which could bring in much-needed cash to reduce debt. The dives...
2024-02-23 11:15:02 ET RBC Capital analyst issues SECTOR PERFORM recommendation for BHC on February 23, 2024 12:00PM ET. The previous analyst recommendation was Sector Perform. BHC was trading at $9.02 at issue of the analyst recommendation. The overall analyst consensus...
2024-02-22 12:30:26 ET Bausch Health Companies Inc. (BHC) Q4 2023 Earnings Conference Call February 22, 2024 8:00 am ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Senior Vice President, Chief Financial Officer (interim) Maria Likur...
2024-02-21 13:11:49 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions extends shelf life of Narcan to 4 years Emergent BioSolutions wins $235.8M DoD contract Seeking Alpha’s Quant Rating on E...
2024-02-21 11:33:14 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch + Lomb draws double downgrade at J.P. Morgan on spinoff concerns Bausch gets Chinese approval for Thermage FLX and TR-4 return pad Seeking...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC Stock Symbol:
NYSE Market:
Bausch Health Companies Inc. Website:
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business...
2024-07-10 00:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of Ne...